Oncolytic Adenovirus Expressing IL-23 and p35 Elicits IFN-γ- and TNF-α-Co-Producing T Cell-Mediated Antitumor Immunity

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Choi, Il Kyu ^a   Li, Yan ^b   Oh, Eonju ^a   Kim, Jaesung ^c   Yun, Chae Ok ^a  

^a Hanyang University   (South Korea)

^b Yonsei University   (South Korea)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; ONCOLYTIC ADENOVIRUS; PROTEIN P35; PROTEIN RDB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOGENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IL 12 GENE; IL 23 GENE; MALE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADENOVIRIDAE; ANIMALS; CYTOKINES; GENE DOSAGE; GENE EXPRESSION; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23; MALE; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; MURINAE; MUS;

EID: 84879763281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067512     Document Type: Article

References (53)

1. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, et al. (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56: 1687-1700.
2. Mapara MY, Sykes M, (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22: 1136-1151.
3. Malmberg KJ, (2004) Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53: 879-892.
4. Podhajcer OL, Lopez MV, Mazzolini G, (2007) Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 18: 183-194.
5. Dranoff G, (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
6. Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, et al. (2006) Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 13: 1010-1020.
7. Li QX, Liu G, Wong-Staal F, (2008) Oncolytic virotherapy as a personalized cancer vaccine. Int J Cancer 123: 493-499.
8. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchieri G, (1994) Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 156: 480-492.
9. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
10. Colombo MP, Trinchieri G, (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168.
11. Haicheur N, Escudier B, Dorval T, Negrier S, De Mulder PH, et al. (2000) Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 119: 28-37.
12. Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, et al. (2003) Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 9: 76-83.
13. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, et al. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168: 5699-5708.
14. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, et al. (2007) Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 178: 7571-7580.
15. Reay J, Kim SH, Lockhart E, Kolls J, Robbins PD, (2009) Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response. Cancer Gene Ther 16: 776-785.
16. Bett AJ, Prevec L, Graham FL, (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67: 5911-5921.
17. Ling P, Gately MK, Gubler U, Stern AS, Lin P, et al. (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154: 116-127.
18. Shimozato O, Ugai S, Chiyo M, Takenobu H, Nagakawa H, et al. (2006) The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 117: 22-28.
19. Hunter CA, (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5: 521-531.
20. Ma X, (2001) TNF-alpha and IL-12: a balancing act in macrophage functioning. Microbes Infect 3: 121-129.
21. Helms T, Boehm BO, Asaad RJ, Trezza RP, Lehmann PV, et al. (2000) Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol 164: 3723-3732.
22. Harari A, Petitpierre S, Vallelian F, Pantaleo G, (2004) Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103: 966-972.
23. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, et al. (2003) HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198: 1909-1922.
24. Cao X, Leonard K, Collins LI, Cai SF, Mayer JC, et al. (2009) Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res 69: 8700-8709.
25. Stoop JN, Woltman AM, Biesta PJ, Kusters JG, Kuipers EJ, et al. (2007) Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 46: 699-705.
26. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR, (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58: 24-38.
27. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y, (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202: 275-293.
28. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
29. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, et al. (2004) Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 101: 4560-4565.
30. Choi IK, Lee JS, Zhang SN, Park J, Sonn CH, et al. (2011) Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Ther 18: 898-909.
31. Huang JH, Zhang SN, Choi KJ, Choi IK, Kim JH, et al. (2010) Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther 18: 264-274.
32. Mizuguchi H, Xu ZL, Sakurai F, Mayumi T, Hayakawa T, (2003) Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum Gene Ther 14: 1265-1277.
33. Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, et al. (1997) A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 159: 2125-2131.
34. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH, (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21: 713-758.
35. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J, (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360: 258-261.
36. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
37. Ranges GE, Figari IS, Espevik T, Palladino MA Jr, (1987) Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166: 991-998.
38. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H, (2000) Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 164: 3645-3651.
39. Xu L, Xu W, Qiu S, Xiong S, (2010) Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 135: 466-475.
40. Wang HY, Wang RF, (2007) Regulatory T cells and cancer. Curr Opin Immunol 19: 217-223.
41. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
42. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243-2247.
43. Elias D, Akuffo H, Britton S, (2005) PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 99: 363-368.
44. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249-2254.
45. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM, (1994) CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med 179: 1367-1371.
46. Bloom BR, Flynn J, McDonough K, Kress Y, Chan J, (1994) Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiology 191: 526-536.
47. Chan J, Xing Y, Magliozzo RS, Bloom BR, (1992) Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175: 1111-1122.
48. Choi KJ, Zhang SN, Choi IK, Kim JS, Yun CO, (2012) Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther 19: 711-723.
49. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, et al. (2006) Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 12: 5859-5868.
50. Pei DS, Zheng JN, (2010) Oncolytic adenoviruses expressing interleukin: a novel antitumour approach. Expert Opin Biol Ther 10: 917-926.
51. Edukulla R, Woller N, Mundt B, Knocke S, Gurlevik E, et al. (2009) Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 69: 1448-1458.
52. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO, (2007) E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 18: 773-786.
53. Zhang SN, Choi IK, Huang JH, Yoo JY, Choi KJ, et al. (2011) Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 19: 1558-1568.